Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438856 | 0.90 | AR (0.65) | ARIGF1R | |
| SCHEMBL12438863 | 0.89 | IGF1R (0.42) | ARIGF1R | |
| SCHEMBL2216371 | 0.87 | PGR (0.56) | AR | |
| SCHEMBL8017366 | 0.85 | TAS2R8 (0.42) | ARIGF1R | |
| SCHEMBL12438861 | 0.83 | AR (0.49) | ARIGF1R | |
| SCHEMBL2217728 | 0.80 | AR (0.52) | ARIGF1R | |
| SCHEMBL2217887 | 0.78 | AR (0.55) | ARIGF1R | |
| SCHEMBL2216810 | 0.78 | AR (0.50) | ARIGF1R | |
| SCHEMBL4028958 | 0.75 | AR (0.67) | AR | |
| SCHEMBL4031735 | 0.74 | AR (0.59) | ARIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| WO-2009097995-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | FABP4, GPR119, PGC | AR 3140/4885IGF1R 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.